new version V2017

glucose lowering for cardiovascular prevention
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

aleglitazar
ALEPREVENTaleglitazarplacebo - EUDRACT201200067116
ALECARDIO, 2014aleglitazarplacebo Exploratory NegativeNCT01042769
alogliptin
EXAMINE, 2013alogliptinplacebo Exploratory NegativeNCT00968708
canagliflozin
CANVAS, 2017canagliflozinplacebo Exploratory Conclusive NCT01032629
dapagliflozin
DECLARE TIMI 58, 2018dapagliflozinplacebo Exploratory - NCT01730534
empagliflozin
EMPA-REG OUTCOME, 2015empagliflozinplacebo Low risk of bias ConclusiveNCT01131676
ertugliflozin
VERTIS CV ongoing ertugliflozinplacebo - NCT01986881
exenatide
EXSCEL, 2017exenatideplacebo Low risk of bias ConclusiveNCT01144338
glargine
ORIGINE, 2012insulin glarginecontrolNegativeNCT00069784
linagliptin
CAROLINA, 2012linagliptinglimepiride Exploratory SuggestingNCT01243424
CARMELINA ongoing linagliptinplacebo - NCT01897532
liraglutide
LEADER, 2016liraglutideplacebo Exploratory ConclusiveNCT01179048
lixisenatide
ELIXAlixisenatideplacebo Exploratory NegativeNCT01147250
pioglitazone
PROACTIVEpioglitazoneplacebo - NCT00174993
IRIS, 2016pioglitazoneplacebo - NCT00091949
saxagliptin
SAVOR TIMI, 2013saxagliptinplacebo Exploratory NegativeNCT01107886
semaglutide
SUSTAIN 6, 2016semaglutideplacebo Exploratory Conclusive NCT01720446
sitagliptin
TECOS, 2015sitagliptinplacebo Exploratory NegativeNCT00790205



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons